Blue Ocean Optoelectronics said on July 27 that it is planning to buy assets through a share issue and cash payment while raising supporting funds, with the target company Suzhou Lancra Technology Co. Because the deal remains uncertain, the company's shares were suspended from the start of trading on July 27, 2026, and it expects to disclose a transaction plan within 10 trading days, according to Jiemian News.

The batch also included several earnings updates. Shuanglin Group said first-half 2026 net profit attributable to shareholders is expected to fall 61.70% to 72.15% year on year to 80 million yuan to 110 million yuan. Dongfang Jinggong reported first-half revenue of 1.691 billion yuan, down 21.68%, and net profit of 3.846 billion yuan, up 867.75%, and proposed a cash dividend of 2 yuan per 10 shares. Shiyao Innovation forecast first-half net profit of 1.18 billion yuan to 1.36 billion yuan, versus a loss of 2.7461 million yuan a year earlier, and said its unit received a 420 million U.S. dollar upfront payment from AstraZeneca on May 29, 2026. Shenhuo Co. reported first-half revenue of 24.791 billion yuan and net profit of 4.781 billion yuan, up 21.35% and 151.06%, respectively.

Separately, Robotek said its wholly owned unit ficonTECService GmbH signed a 16.74 million euro contract, or about 129 million yuan before tax, on July 23 with a subsidiary of a New York-listed company for automated manufacturing equipment and services used in mass production of optical components such as fiber array units. Several other companies announced product registration progress, including Saisheng Pharma, ST Renfu and Sinomedical, while Saibo Medical said its coronary stent balloon dilatation catheter obtained a medical device registration certificate in Vietnam.

A number of listed companies also disclosed buyback or shareholding plans, including Suobo Protein, ST Zhongzhu, Fenglong, Tederic, Yinzhen, Fabon, Huawu, Wuchan Jinlun, Zhongli, Ningbo Yunsheng, Xingyu, iFLYTEK, Tongxing and Honggong.